Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
BeovuⓇ - Anti-VEGF
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04047472 HOBBY (CRTH258A2307)
Macular degeneration
Phase 3
494
Change from baseline in best-corrected visual acuity (BCVA) at week 48
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2 mg/50 μL
Chinese patients with neovascular age-related macular degeneration
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
References
Abbreviations
Hematology
Biosimilars
Global Health
80 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation